Prescription of anti-influenza drugs in Japan, 2014-2020: a retrospective study using open data from the national claims database
Authors:
Preprint
Abstract
Background: Both physicians and patients are proactive towards managing seasonal influenza in Japan and six drugs are approved. We aimed to clarify the status of anti-influenza drug use by analyzing real-world data. Methods: This retrospective study analyzed open data from the National Database of Health Insurance Claims and Specific Health Checkups, which covers most claims data from national health insurance. We estimated the annual number of patients prescribed anti-influenza drugs, their age and sex distribution, drug costs, and regional disparities for the period 2014-2020. Results: For 2014-2019, an estimated 6.7-13.4 million patients per year were prescribed anti-influenza drugs, with an annual cost of 22.3-48.0 billion JPY (Japanese Yen). In addition, 21.1-32.0 million rapid antigen tests were performed at a cost of 30.1-47.1 billion JPY. In 2017, laninamivir was the most frequently prescribed anti-influenza drug (48%), followed by oseltamivir (36%), while in 2018, the newly introduced baloxavir accounted for 40.8% of prescriptions. After the emergence of COVID-19, the number of patients prescribed anti-influenza drugs in 2020 dropped to just 14,000. In 2018, 37.6% of prescriptions were for patients aged < 20 years compared with 12.2% for those aged ≥ 65 years. Prescriptions for inpatients accounted for 1.1%, and the proportion of prescriptions for inpatients increased with age. Male were more likely than female to be prescribed anti-influenza drugs for inpatient. Conclusions: Based on our clarification of how influenza is clinically managed in Japan, future work should evaluate the clinical and economic aspects of proactively prescribing anti-influenza drugs.Keywords
All Related Versions
- Published version: PLOS ONE, 18 (10), e0291673.
This publication has 39 references indexed in Scilit:
- Age and Sex Differences in Rates of Influenza-Associated Hospitalizations in Hong KongAmerican Journal of Epidemiology, 2015
- Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trialsThe Lancet, 2015
- Evaluation of Estimated Number of Influenza Patients from National Sentinel Surveillance Using the National Database of Electronic Medical ClaimsJapanese Journal of Infectious Diseases, 2015
- Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory commentsBMJ, 2014
- Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory commentsBMJ, 2014
- A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseasesJournal of Infection and Chemotherapy, 2013
- Clinical Features of Infants Hospitalized for 2009 Pandemic Influenza A (H1N1) in JapanThe Pediatric Infectious Disease Journal, 2012
- Widespread use of neuraminidase inhibitors in JapanJournal of Infection and Chemotherapy, 2011
- Long‐Acting Neuraminidase Inhibitor Laninamivir Octanoate versus Oseltamivir for Treatment of Influenza: A Double‐Blind, Randomized, Noninferiority Clinical TrialClinical Infectious Diseases, 2010
- Japanese Practicing Physicians' Relationships with Pharmaceutical Representatives: A National SurveyPLOS ONE, 2010